168 related articles for article (PubMed ID: 38615745)
1. Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety.
Wang KN; Zhou K; Zhong NN; Cao LM; Li ZZ; Xiao Y; Wang GR; Huo FY; Zhou JJ; Liu B; Bu LL
Life Sci; 2024 Jun; 346():122635. PubMed ID: 38615745
[TBL] [Abstract][Full Text] [Related]
2. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
Kim BH; Yi EH; Ye SK
Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
[TBL] [Abstract][Full Text] [Related]
3. The role of STAT3 signaling in mediating tumor resistance to cancer therapy.
Tan FH; Putoczki TL; Stylli SS; Luwor RB
Curr Drug Targets; 2014; 15(14):1341-53. PubMed ID: 25410411
[TBL] [Abstract][Full Text] [Related]
4. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
5. Targeting transcription factor STAT3 for cancer prevention and therapy.
Chai EZ; Shanmugam MK; Arfuso F; Dharmarajan A; Wang C; Kumar AP; Samy RP; Lim LH; Wang L; Goh BC; Ahn KS; Hui KM; Sethi G
Pharmacol Ther; 2016 Jun; 162():86-97. PubMed ID: 26478441
[TBL] [Abstract][Full Text] [Related]
6. Highlighted STAT3 as a potential drug target for cancer therapy.
Lee H; Jeong AJ; Ye SK
BMB Rep; 2019 Jul; 52(7):415-423. PubMed ID: 31186087
[TBL] [Abstract][Full Text] [Related]
7. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV
Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906
[TBL] [Abstract][Full Text] [Related]
8. Signal transducer and activator of transcription 3 inhibitors: a patent review.
Page BD; Ball DP; Gunning PT
Expert Opin Ther Pat; 2011 Jan; 21(1):65-83. PubMed ID: 21114420
[TBL] [Abstract][Full Text] [Related]
9. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.
Dong J; Cheng XD; Zhang WD; Qin JJ
J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.
Masciocchi D; Gelain A; Villa S; Meneghetti F; Barlocco D
Future Med Chem; 2011 Apr; 3(5):567-97. PubMed ID: 21526897
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
[TBL] [Abstract][Full Text] [Related]
12. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.
Mankan AK; Greten FR
Expert Opin Investig Drugs; 2011 Sep; 20(9):1263-75. PubMed ID: 21751940
[TBL] [Abstract][Full Text] [Related]
14. Targeting STAT3 in Cancer Immunotherapy.
Zou S; Tong Q; Liu B; Huang W; Tian Y; Fu X
Mol Cancer; 2020 Sep; 19(1):145. PubMed ID: 32972405
[TBL] [Abstract][Full Text] [Related]
15. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
16. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J
BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346
[TBL] [Abstract][Full Text] [Related]
17. Targeting STAT3 in cancer: how successful are we?
Yue P; Turkson J
Expert Opin Investig Drugs; 2009 Jan; 18(1):45-56. PubMed ID: 19053881
[TBL] [Abstract][Full Text] [Related]
18. STAT proteins as novel targets for cancer drug discovery.
Turkson J
Expert Opin Ther Targets; 2004 Oct; 8(5):409-22. PubMed ID: 15469392
[TBL] [Abstract][Full Text] [Related]
19. An update on investigational therapies that target STAT3 for the treatment of cancer.
Santoni M; Miccini F; Cimadamore A; Piva F; Massari F; Cheng L; Lopez-Beltran A; Montironi R; Battelli N
Expert Opin Investig Drugs; 2021 Mar; 30(3):245-251. PubMed ID: 33599169
[TBL] [Abstract][Full Text] [Related]
20. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.
Santoni M; Massari F; Del Re M; Ciccarese C; Piva F; Principato G; Montironi R; Santini D; Danesi R; Tortora G; Cascinu S
Expert Opin Investig Drugs; 2015 Jun; 24(6):809-24. PubMed ID: 25746129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
